The company continues to expect full year 2026 U.S. procedure growth to be in the range of 39% to 48% compared to the prior year period. The company continues to expect full year 2026 gross margin to be approximately 65%. The company continues to expect full year 2026 adjusted EBITDA* loss to be in the range of $30 million to $17 million.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PRCT:
- Procept BioRobotics reports Q1 EPS (56c), consensus (55c)
- PROCEPT BioRobotics: Depressed Valuation, Transitory Destocking, and Underappreciated Multi‑Year Growth Runway Support Buy Rating
- Procept BioRobotics announce international launch of HYDROS Robotic
- PROCEPT BioRobotics Adds Independent Director to Audit Committee
- Procept BioRobotics initiated with a Neutral at Baird